OverviewSuggest Edit

Amphastar Pharmaceuticals, Inc. is a recognized specialty pharmaceutical company that uses state-of-the-art, cGMP compliant facilities to develop, manufacture, and market injectable and inhalation products. Amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. Its products include Enoxaparin Sodium Injection, Cortrosyn, Amphadase, Emergency Syringes in Luer-Jet, Lidocaine, Naloxone, and Phytonadione Injection.

TypePublic
Founded1996
HQRancho Cucamonga, US
Websiteamphastar.com
Employee Ratings2.3

Latest Updates

Employees (est.) (Dec 2018)2,078(+27%)
Job Openings3
Revenue (FY, 2018)$294.7 M(+23%)
Share Price (Dec 2019)$19 (-2%)

Key People/Management at Amphastar Pharmaceuticals

Jack Y. Zhang

Jack Y. Zhang

Chief Executive Officer, Chief Science Officer, and Director
Mary Z. Luo

Mary Z. Luo

Chief Operating Officer, Chief Scientist, and Chairman of the Board of Directors
Jason B. Shandell

Jason B. Shandell

President and Director
Richard Koo

Richard Koo

Director
Richard Prins

Richard Prins

Director
Howard Lee

Howard Lee

Director
Show more

Amphastar Pharmaceuticals Office Locations

Amphastar Pharmaceuticals has offices in Rancho Cucamonga, Nanjing Shi and Éragny-sur-Epte
Rancho Cucamonga, US (HQ)
11570 6th St
Nanjing Shi, CN
86 Xingang Ave, Qixia Qu
Éragny-sur-Epte, FR
1 Route Nationale 15 Paris Dieppe
Show all (3)

Amphastar Pharmaceuticals Financials and Metrics

Amphastar Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Amphastar Pharmaceuticals's revenue was reported to be $294.67 m in FY, 2018
USD

Revenue (Q3, 2019)

80.1m

Gross profit (Q3, 2019)

35.3m

Gross profit margin (Q3, 2019), %

44%

Net income (Q3, 2019)

1.3m

EBIT (Q3, 2019)

2.4m

Market capitalization (2-Dec-2019)

893.7m

Closing stock price (2-Dec-2019)

19.0

Cash (30-Sept-2019)

85.6m

EV

853.1m
Amphastar Pharmaceuticals's current market capitalization is $893.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

210.5m251.5m255.2m240.2m294.7m

Revenue growth, %

20%1%

Cost of goods sold

159.2m174.2m151.0m149.4m187.7m

Gross profit

51.3m77.3m104.2m90.8m107.0m
Quarterly
Annual
usdY, 2012Y, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

50.2m53.6m67.8m66.1m72.4m65.6m86.3m

Accounts Receivable

22.9m33.2m26.8m36.0m52.2m

Prepaid Expenses

9.8m5.5m

Inventories

118.4m63.6m69.3m
Annual
usdFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(10.7m)(2.8m)10.5m4.5m(6.7m)

Depreciation and Amortization

12.0m15.4m16.5m

Inventories

9.1m(9.7m)18.7m(6.0m)

Accounts Payable

7.0m6.7m29.2m
USDY, 2019

EV/EBIT

354.9 x

EV/CFO

23.6 x

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.4 x
Show all financial metrics

Amphastar Pharmaceuticals Operating Metrics

FY, 2016

Facilities

5

Products

19
Show all operating metrics

Amphastar Pharmaceuticals Revenue Breakdown

Embed Graph

Amphastar Pharmaceuticals revenue breakdown by business segment: 94.1% from Finished pharmaceutical products and 5.9% from Active Pharmaceutical Ingredients

Amphastar Pharmaceuticals Online and Social Media Presence

Embed Graph

Amphastar Pharmaceuticals News and Updates

Amphastar Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference

RANCHO CUCAMONGA, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 1:00 p.m. Easte…

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

RANCHO CUCAMONGA, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President will be presenting at the Jefferies London Healthcare Conference on Thursday, November 21, 2019 at 3:20 p.m. GMT in Aldwych, London, UK.

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7th, 2019

RANCHO CUCAMONGA, Calif., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its third quarter of 2019 ended September 30th, 2019, after the market closes on Thursday, November 7th, 2019, and will hold a conference c…

Amphastar Pharmaceuticals to Present at the Wells Fargo 2019 Healthcare Conference

RANCHO CUCAMONGA, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO, will be presenting at the Wells Fargo 2019 Healthcare Conference on Thursday, September 5, 2019 at 3:05 p.m. Eastern Time…

Amphastar Pharmaceuticals to Present at the Raymond James Life Sciences and MedTech Healthcare Conference

RANCHO CUCAMONGA, Calif., June 14, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, will be presenting at the Raymond James Life Sciences and MedTech Healthcare Conference on Wednesday, June 19, 2019 at 4:10 p.m. Eastern Time, New York,…

Amphastar Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

RANCHO CUCAMONGA, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO, will be presenting at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 8:30 a.m. Eastern Time, New Yo…
Show more

Amphastar Pharmaceuticals Frequently Asked Questions

  • When was Amphastar Pharmaceuticals founded?

    Amphastar Pharmaceuticals was founded in 1996.

  • Who are Amphastar Pharmaceuticals key executives?

    Amphastar Pharmaceuticals's key executives are Jack Y. Zhang, Mary Z. Luo and Jason B. Shandell.

  • How many employees does Amphastar Pharmaceuticals have?

    Amphastar Pharmaceuticals has 2,078 employees.

  • What is Amphastar Pharmaceuticals revenue?

    Latest Amphastar Pharmaceuticals annual revenue is $294.7 m.

  • What is Amphastar Pharmaceuticals revenue per employee?

    Latest Amphastar Pharmaceuticals revenue per employee is $141.8 k.

  • Who are Amphastar Pharmaceuticals competitors?

    Competitors of Amphastar Pharmaceuticals include Mylan, Generex Biotechnology and E-Therapeutics.

  • Where is Amphastar Pharmaceuticals headquarters?

    Amphastar Pharmaceuticals headquarters is located at 11570 6th St, Rancho Cucamonga.

  • Where are Amphastar Pharmaceuticals offices?

    Amphastar Pharmaceuticals has offices in Rancho Cucamonga, Nanjing Shi and Éragny-sur-Epte.

  • How many offices does Amphastar Pharmaceuticals have?

    Amphastar Pharmaceuticals has 3 offices.